Abiopharma

🔍 Dickinson Andrew D (Executive)

Company: GILEAD SCIENCES, INC. (GILD)

Report Date: 2025-12-10

Detailed Transactions and Holdings:

• Acquired 3,693 shares of Common Stock (Direct)
  Date: 2025-12-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 158,248.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,745 shares of Common Stock at $121.34 per share (Direct)
  Date: 2025-12-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 156,503.00 | transaction_form_type: 4
• Sold 3,693 shares of Restricted Stock Unit (Derivative)
  Date: 2025-12-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 27,526.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.